FDA Approves Ustekinumab Biosimilar Steqeyma, the Seventh of Its KindDecember 19, 2024DermatologyGastroenterologyMusculoskeletal Disorders
Pyzchiva Receives FDA Approval as Third Ustekinumab BiosimilarJuly 2, 2024Rare DiseasesMusculoskeletal DisordersDermatologyGastroenterology
FDA Approves Polyarticular JIA Indication for SarilumabJune 12, 2024Rare DiseasesMusculoskeletal Disorders
FDA Grants New Pediatric Arthritis Indications for UpadacitinibJune 7, 2024Rare DiseasesMusculoskeletal DisordersGastroenterologyDermatology
Second FDA-Approved Tocilizumab Biosimilar Has Intravenous, Subcutaneous FormulationsMarch 8, 2024Rare DiseasesMusculoskeletal Disorders
FDA Removes Harmful Chemicals From Food PackagingMarch 1, 2024Mixed TopicsDiabetesObesityBusiness of MedicineCardiologyEndocrinologyNeurology
FDA Approves 10th Humira Biosimilar, With InterchangeabilityFebruary 27, 2024GastroenterologyRare DiseasesMusculoskeletal DisordersDermatology
FDA warns of potentially lethal reaction to seizure medsNovember 29, 2023NeurologyDermatologyImmunologyMixed Topics
